Great article in AFR today with SG Hiscock :What’s a stock you like that (most) investors wouldn’t have heard of?
We think Argenica Therapeutics, while still at an early stage, has IP which is showing huge promise. Their lead asset, ARG-007, is a neuroprotective peptide designed to protect brain cells and reduce cell death following strokes and other acute brain injuries.
The company is currently conducting a phase two clinical trial of ARG-007 for acute ischemic stroke in multiple hospitals across Australia. The trial will evaluate the safety and efficacy of the asset in reducing brain cell death and improving patient outcomes.
AGN Media thread, page-84
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.0¢ |
Change
-0.015(1.78%) |
Mkt cap ! $102.6M | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 85.5¢ | 82.0¢ | $69.84K | 82.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2733 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.5¢ | 3700 | 1 |
View Market Depth
| Last trade - 15.58pm 05/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |